ASIT+™ technology’s benefits in treating grass pollen rhinitis presented during a scientific session at Medical Research Council & Asthma UK Centre in London

Dr. Mohamed Shamji, Scientific Advisor of ASIT Biotech and Associate Professor at Imperial College London, presented safety and efficacy data of the gp-ASIT+™’s phase 2 study

BRUSSELS--(BUSINESS WIRE)-- Regulatory News:

ASIT biotech (Paris: ASIT) (BSE: ASIT) (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that ASIT+™ technology’s use in grass pollen rhinitis was presented on December 2, 2016 during a scientific session at Medical Research Council (MRC) & Asthma UK Centre in London.

The presentation was led by Dr. Mohamed Shamji, Scientific Advisor of ASIT Biotech and Associate Professor at Imperial College London, and took place at MRC & Asthma UK Centre at St Thomas’ Hospital in London. The Centre was formed in October 2005 as a partnership between the MRC, Asthma UK charity, Imperial College and King's College London, as well as the NHS Trusts of the two universities.

Dr. Shamji’s presentation covered a novel approach to treat patients with summer hay fever (seasonal allergic rhinitis) which affect 40% of the global population. More importantly, the lecture specifically highlighted the joint effort between ASIT biotech and Imperial College London to develop novel therapeutic strategies to tackle a serious medical unmet need in the treatment of seasonal allergic rhinitis. His presentation discussed the characterisation of natural pollen peptides using ASIT+™ technology platform as well as data illustrating that a short course of Lolium Perenne peptide injections (gp-ASIT+™) is safe and effective in grass pollen-induced seasonal allergic rhinitis. It summarized the results of the phase II clinical studies previously disclosed by ASIT biotech.

gp-ASIT+™ is the Company’s most advanced drug candidate. Its clinical efficacy is being investigated in a phase III clinical trial in Europe. The results of this study should be available during the first quarter of 2017.

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+TM technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+TM and house dust mite: hdm-ASIT+TM), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.

Forward Looking Statements

All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Important Legal Notice

This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The Company is responsible for the information contained in this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161205006108/en/

Company
ASIT biotech
Thierry Legon, CEO, +32 2 264 03 90
[email protected]
or
Media and Investor Relations - France
NewCap
Dusan Oresansky / Pierre Laurent, +33 1 44 71 94 92
[email protected]
or
Media Relations - Belgium
Laure-Eve Monfort, +32 2 290 90 93
[email protected]

Source: ASIT biotech

You May Also Be Interested In

• Composition of the Nomination Committee of Orion Corporation
• Orderific Announces Launch of DeliveryDart: Innovating Independence for Food Delivery Drivers
• Information relating to the total number of voting rights and shares making up the share capital at 26 April 2024 – post blocs acquisition by the Consortium